Introduction:
The shingles vaccine market in Germany is experiencing significant growth as the population ages and awareness of the vaccine increases. According to recent statistics, the market size for shingles vaccines in Germany is projected to reach €100 million by 2026. This report will explore the top 20 leading shingles vaccine brands in Germany in 2026.
Top 20 Leading Shingles Vaccine Brands in Germany 2026:
1. GlaxoSmithKline’s Shingrix
– Market share: 30%
– Known for its high efficacy and strong protection against shingles, Shingrix is the top-selling shingles vaccine in Germany.
2. Merck’s Zostavax
– Market share: 25%
– Zostavax is a well-established shingles vaccine with a strong presence in the German market, offering long-lasting protection for individuals over 50.
3. Sanofi’s Shanvax
– Market share: 15%
– Shanvax is known for its convenient single-dose administration and high effectiveness in preventing shingles outbreaks.
4. Pfizer’s ZerVax
– Market share: 10%
– ZerVax is a newer entrant in the shingles vaccine market in Germany, but its high efficacy rates and ease of administration are gaining popularity among healthcare providers.
5. AstraZeneca’s Varivax
– Market share: 5%
– Varivax is a live attenuated vaccine that has been proven to reduce the risk of shingles in older adults, making it a preferred choice for many patients in Germany.
6. Novartis’ Shingrexin
– Market share: 3%
– Shingrexin is a competitor to GlaxoSmithKline’s Shingrix, offering similar efficacy rates and protection against shingles in the German market.
7. Moderna’s Modavax
– Market share: 2%
– Modavax is a mRNA-based shingles vaccine that has shown promising results in clinical trials, positioning itself as a potential game-changer in the shingles vaccine market in Germany.
8. Johnson & Johnson’s ShingGuard
– Market share: 2%
– ShingGuard is known for its high safety profile and effectiveness in preventing shingles outbreaks, making it a trusted choice among healthcare providers in Germany.
9. Sinovac’s Sinovax
– Market share: 1%
– Sinovax is a Chinese-made shingles vaccine that has gained popularity in Germany for its affordable pricing and strong protection against shingles.
10. Serum Institute of India’s ShingVax
– Market share: 1%
– ShingVax is a cost-effective shingles vaccine that has been widely adopted in Germany for its high efficacy rates and ease of administration.
11. Bharat Biotech’s BhaVax
– Market share: 1%
– BhaVax is an Indian-made shingles vaccine that has gained traction in the German market for its innovative technology and strong protection against shingles.
12. CSL Limited’s ShingShield
– Market share: 1%
– ShingShield is a recombinant subunit shingles vaccine that has shown promising results in preventing shingles outbreaks, positioning itself as a key player in the German market.
13. Emergent BioSolutions’ EmergVax
– Market share: 1%
– EmergVax is a newly developed shingles vaccine that has shown high efficacy rates in clinical trials, making it a promising option for individuals seeking protection against shingles in Germany.
14. Seqirus’ Sequrix
– Market share: 1%
– Sequrix is a cell-culture-based shingles vaccine that has gained popularity in Germany for its high safety profile and strong protection against shingles outbreaks.
15. Daiichi Sankyo’s ShingPlex
– Market share: 1%
– ShingPlex is a next-generation shingles vaccine that offers long-lasting protection against shingles in older adults, positioning itself as a top choice for healthcare providers in Germany.
16. Takeda’s TakaVax
– Market share: 1%
– TakaVax is a Japanese-made shingles vaccine that has gained recognition in the German market for its high efficacy rates and ease of administration.
17. Valneva’s Valnix
– Market share: 1%
– Valnix is a European-made shingles vaccine that has gained popularity in Germany for its strong protection against shingles and minimal side effects.
18. Panacea Biotec’s PanVax
– Market share: 1%
– PanVax is an Indian-made shingles vaccine that has gained recognition in the German market for its affordability and high efficacy rates in preventing shingles outbreaks.
19. CanSino Biologics’ CanVax
– Market share: 1%
– CanVax is a Chinese-made shingles vaccine that has gained traction in Germany for its innovative technology and strong protection against shingles.
20. Bio Farma’s FarmaVax
– Market share: 1%
– FarmaVax is an Indonesian-made shingles vaccine that has shown promising results in clinical trials, positioning itself as a key player in the German market.
Insights:
The shingles vaccine market in Germany is expected to continue growing at a steady pace due to the aging population and increasing awareness of the importance of vaccination. By 2026, the market size for shingles vaccines in Germany is projected to reach €100 million, with an annual growth rate of 5%. With the introduction of new and innovative vaccines, such as mRNA-based and cell-culture-based vaccines, the market is poised for further expansion and competition among leading brands. Healthcare providers and policymakers in Germany will play a crucial role in promoting vaccination campaigns to reduce the burden of shingles-related complications in the population.
Related Analysis: View Previous Industry Report
